N/A N=400 Behavioral Economics Trial To Enhance Regulation of Blood Pressure (BETTER-BP)
High Blood Pressure
Primary: Change in Systolic Blood Pressure (SBP) — -6.7; -5.8 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=708 Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)
COPD (Chronic Obstructive Pulmonary Disease)
Primary: Change From Baseline in Pre-dose Forced Expiratory Volume Within the First Second (FEV1) at Week 24 — 0.030; -0.032 Liters — p=< 0.001
N/A N=35 CairnSurgical Breast Cancer Locator (BCL) Post-Market Study
Breast Cancer
Primary: Positive Margin Rate — 2 Participants
Phase 4 N=70 Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi
Invasive Fungal Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 55; 9 Participants
Phase 1 N=39 A Study of Two Different Formulations of LY3502970 in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 in Formulation 1 and Formulation 2 — 86.5; 86.5 nanogram per milliliter (ng/mL)
N/A N=296 Changes in Biomarker of Exposure in Adults Who Smoke Cigarettes Switching From Cigarettes to Heated Tobacco Products
Tobacco Use
Primary: Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) — 170.800; 174.464; 194.995; 228.143 pg/mg creatinine — p=<.0001
Phase 1 N=10 A Phase I Study of LY3502970 in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Absolute Bioavailability of LY3502970 — 77 Percentage
Phase 1 N=16 Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers
Healthy Volunteers
Primary: Incidence of Abnormal Physical Exam Findings — 0; 0; 0 Participants
Phase 2 N=20 A Trial of Vitamin B12 in Septic Shock
Septic Shock
Primary: Feasibility of Clinical and Protocol Completion — 10; 10 Participants
Phase 3 N=69 An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis · MG - Myasthenia Gravis · gMG
Primary: Mean of the Average MG-ADL Total Score Change From Baseline During the Visit of Week 1 Through Week 21 by Regimen Arm — -5.13; -4.61 Score on a scale
N/A N=523 Accuracy of the New Barrett TAL Formula With the Argos Measurements: A Multicenter Prospective Study
Cataract
Primary: The Percentage of Eyes That Achieve a Postoperative Manifest Spherical Equivalent Refraction ≤ ±0.50 D. — 489 Eyes
N/A N=122 A Brief Cognitive Task Intervention for NHS Staff Affected by COVID-19 Trauma (GAINS-2 Study)
Intrusive Memories of Traumatic Event(s)
Primary: Number of Intrusive Memories of Traumatic Event(s) — 6.50; 9.0; 11.5; 5.0 Number of intrusive memories
Phase 4 N=115 Reducing Hypotensive Anesthesia Use With TXA During Orthognathic Surgery
Hypotension During Surgery · Blood Loss, Surgical
Primary: Surgeon's Analysis of Surgical Field Visualization — 1.3 score on a scale
N/A N=27 Comparative Study of MCCE With/Without Tether vs Conventional Upper Endoscopy in Patients With Upper Abdominal Symptoms
Upper Gastrointestinal Symptoms
Primary: Compare Total Number of Lesions Identified Via MCCE Versus EGD — 10; 12 # of lesions identified
Phase 4 N=26 Impact of Astaxanthin on Cognition in Recreationally Active Females
Mental Fatigue
Primary: Reaction Time — 402.7; 400; 426.4; 406.6 milliseconds